
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is supported by two approved, royalty-generating assets that materially de-risk the story: Icotyde produced broad early launch momentum with more than 20,000 patients initiating therapy and nearly 9,000 prescribers, while Mimrylo added a second stream after approval in August and helped drive $274.4M of 3Q26 collaboration revenue and $3.07 diluted EPS. Its outlook is further strengthened by a well-capitalized balance sheet of $834.6M in cash, cash equivalents, and marketable securities, plus up to $300M of share repurchases, which should fund a wholly owned pipeline without immediate dilution. The pipeline adds upside through PN-881, PN-477, PN-458, and PN-8047, with clinically validated targets, encouraging Phase 1 data, and multiple readouts expected in 1Q27, early 1Q27, and 1H28.
Bears say
Protagonist Therapeutics is facing a negative outlook because its value depends heavily on unproven clinical programs and partnered commercialization, both of which carry meaningful execution risk if FDA or EMA approvals are delayed or denied. The company also faces intense competition in inflammation and immunology, including entrenched products and other oral candidates, which could restrict uptake for icotrokinra and any wholly owned assets, while higher-than-expected spending on the pipeline could pressure financial performance. Even rusfertide’s development is not without setbacks, as discontinuation rates due to treatment-emergent adverse events reached 5.5% versus 2.7% for placebo, and broader portfolio risk is amplified by the history of oral IL-17 failures and unpredictable regulatory outcomes.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Protagonist Therapeutics (PTGX) Forecast
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares